Hints and tips:
Related Special Reports
...Its flagship fund, the Innovation ETF, which is dominated by holdings in electric car maker Tesla, streaming company Roku and biotech Crispr Therapeutics, appreciated by 150 per cent last year....
...Delysium / KUROSEMI INC. ??? Orderly ??? Sui Token Warrant ???...
...Perhaps it was the therapeutic nature of endlessly circling something, or simply a coping mechanism to make up for the lack of competitive professional sport, but gliding around the streets of Monte Carlo...
...The partnership was set up to discover therapeutic antibodies. One success was Dupixent, which treats allergic diseases such as eczema and asthma....
...Francis S Collins, director of the NIH, said: “Now is the time to come together with unassailable objectivity to swiftly advance the development of the most promising vaccine and therapeutic candidates that...
...Many of the defendants have teamed up to offer $48bn to settle these suits — but so far, many states are holding out for more....
...Two of the companies appear to have been MabVax Therapeutics and Biozone, according to the partial Seeking Alpha headlines referenced in the complaint....
...He was “uniquely qualified to take on this role given his track record of success in highly scientific and competitive therapeutic areas, deep understanding of the evolving healthcare environment around...
...(FT) News round-up Roche to buy Spark Therapeutics in $4.8bn deal (FT) JAB enters pet industry with bid for US veterinary clinics (FT) Provident rebuffs rival’s ‘irresponsible’ hostile takeover offer...
...Shire’s haemophilia business also faces a potential threat from experimental gene therapies being developed by BioMarin, Spark Therapeutics and Pfizer, which are designed to fix the underlying genetic defect...
...Now GlaxoSmithKline, the largest UK drug manufacturer by sales, is teaming up with Alphabet, Google’s holding company, to develop an entirely different approach for the 21st century: bioelectronics....
...A version of this article was first published by the Nikkei Asian Review on July 11, 2018. ©2018 Nikkei Inc. All rights reserved....
...According to Ben Shepherd, director of therapeutics at Organovo, the challenges ahead are about increasing the size of the tissue that can be grown....
...combines an insurer with a PBM, such as UnitedHealth, which cuts deals with drugmakers through its OptumRx division, and a consortium of Blue Cross Blue Shield state health plans, which negotiate via Prime Therapeutics...
...Sanofi said it would pay $11.6bn for the haemophilia specialist Bioverativ, a 63 per cent premium, while Celgene agreed to pay $9bn for Juno Therapeutics, a cellular therapy company — almost two times as...
...Biotechnology company Avenue Therapeutics and bank holding company Esquire Financial Holdings were trading higher on Tuesday after pricing late on Monday....
...It presented at the JPMorgan healthcare conference earlier this year and is holding a research and development day in New York later this month....
...Some of its holdings also have limited liquidity. For every C$5m (US$3.7m) of new ETF units that the sponsors create, they would need to buy a fifth of the daily volume of CanniMed Therapeutics....
...A powerful new force in bioelectronics – using electrical signals rather than chemical or biological drugs to treat disease – has been created by GlaxoSmithKline in partnership with Alphabet, Google’s holding...
...Shares in Celldex Therapeutics fell 53.7 per cent to $3.79, after the biopharmaceutical company said it would discontinue a late-stage study of its brain cancer treatment, Rintega, after an independent interim...
...“You do need critical mass in [core] therapeutic areas . . . but just being an enormous pharmaceuticals company is not the criteria.”...
...“This proposed merger, and so-called ‘inversions’ by other companies, will leave US taxpayers holding the bag,” Mrs Clinton said, adding that she would soon propose “specific steps to prevent these kind...
The pharmaceuticals industry is in a bullish mood over immunotherapies
...Nasdaq-listed Insys Therapeutics, whose drugs include a synthetic cannabidiol formulation, trades at 22 times forward earnings....
...Amgen, the big US biotech group, in January agreed an R&D collaboration worth up to $585m with Kite Pharma, a Californian company that, together with Seattle-based Juno Therapeutics, is vying with Novartis...
International Edition